Objective:

To determine whether seropositivity in rheumatoid arthritis patients treated with adalimumab (ADL) is associated with the presence of anti-adalimumab (anti-ADL) antibodies.

Materials and methods:

A descriptive observational study that included patients diagnosed with rheumatoid arthritis according to ACR 1987 criteria, and who were on treatment with ADL as the first biological, for at least six months. All patients were evaluated for rheumatoid factor, anti-citrulline antibodies, erythrocyte sedimentation rate, C-reactive protein, clinimetric indices, and level of anti-ADL antibodies.

Results:

A total of 80 patients with a mean age of 56 years were evaluated, of whom 86% were women. The mean duration of the disease was 15 years, and the ADL exposure time was 52 months (median value). The seropositivity for rheumatoid factor tended to be higher in patients who developed anti-ADL antibodies compared to those who did not (90.5% vs. 66.1%). The magnitude of the association between rheumatoid factor and the presence of anti-ADL antibodies was shown to be strong and statistically significant (OR = 4.87, 95% CI; 1.03-23.03). Adjusted multivariate regression analyses showed a strong association (OR = 9.77, 95% CI; 1.74-54.79) between seropositivity and the presence of anti-ADL antibodies, which, given the low number of patients, lacks precision (95% CI very wide).

Conclusions:

Seropositive patients tend to have more anti-ADL antibodies. However, a larger sample size is required to obtain the necessary precision and greater certainty in these findings.

        · resumo em Espanhol     · texto em Inglês | Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )